{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:19:24Z","timestamp":1767147564904,"version":"build-2238731810"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.pharep.2013.08.011","type":"journal-article","created":{"date-parts":[[2014,2,19]],"date-time":"2014-02-19T17:21:11Z","timestamp":1392830471000},"page":"107-113","source":"Crossref","is-referenced-by-count":12,"title":["The effects of selected inhibitors of histone modifying enzyme on C6 glioma cells"],"prefix":"10.1007","volume":"66","author":[{"given":"Marta","family":"Maleszewska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Steranka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bozena","family":"Kaminska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10.1016\/j.pharep.2013.08.011_bib0005","doi-asserted-by":"crossref","first-page":"8884","DOI":"10.1523\/JNEUROSCI.0968-09.2009","article-title":"BMI1 sustains human glioblastoma multiforme stem cell renewal","volume":"29","author":"Abdouh","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharep.2013.08.011_bib0010","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1517\/13543784.2012.694425","article-title":"Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results","volume":"21","author":"Berendsen","year":"2012","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.pharep.2013.08.011_bib0015","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1016\/j.febslet.2011.10.018","article-title":"The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response","volume":"585","author":"Bernhard","year":"2011","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharep.2013.08.011_bib0020","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1349-7006.2010.01792.x","article-title":"Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas","volume":"102","author":"Campos","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1016\/j.pharep.2013.08.011_bib0025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.gde.2004.02.001","article-title":"The functions of E(Z)\/EZH2-mediated methylation of lysine 27 in histone H3","volume":"14","author":"Cao","year":"2004","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.pharep.2013.08.011_bib0030","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ijc.26057","article-title":"Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo","volume":"130","author":"Catalano","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pharep.2013.08.011_bib0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: from mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.pharep.2013.08.011_bib0040","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-1-61779-612-8_8","article-title":"The epigenetics of brain tumors","volume":"863","author":"Dubuc","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.pharep.2013.08.011_bib0045","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1476-4598-8-14","article-title":"GSK3 beta N-terminus binding to p53 promotes its acetylation","volume":"8","author":"Eom","year":"2009","journal-title":"Mol Cancer"},{"key":"10.1016\/j.pharep.2013.08.011_bib0050","doi-asserted-by":"crossref","first-page":"475641","DOI":"10.1155\/2011\/475641","article-title":"Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors","volume":"2011","author":"Federico","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.pharep.2013.08.011_bib0055","doi-asserted-by":"crossref","first-page":"9078","DOI":"10.1128\/JVI.00836-11","article-title":"Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2","volume":"85","author":"Friedman","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.pharep.2013.08.011_bib0060","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrg3173","article-title":"Histone methylation: a dynamic mark in health, disease and inheritance","volume":"13","author":"Greer","year":"2012","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.pharep.2013.08.011_bib0065","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00441-002-0651-7","article-title":"Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion","volume":"310","author":"Grobben","year":"2002","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.pharep.2013.08.011_bib0070","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4155\/fmc.12.3","article-title":"Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed","volume":"4","author":"Gryder","year":"2012","journal-title":"Future Med Chem"},{"key":"10.1016\/j.pharep.2013.08.011_bib0075","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2217\/epi.12.52","article-title":"A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(\u00ae))","volume":"4","author":"Harrison","year":"2012","journal-title":"Epigenomics"},{"key":"10.1016\/j.pharep.2013.08.011_bib0080","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-008-0376-0","article-title":"Copy number alterations of the polycomb gene BMI1 in gliomas","volume":"116","author":"H\u00e4yry","year":"2008","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.pharep.2013.08.011_bib0085","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s12031-009-9284-6","article-title":"Trichostatin A stimulates steroid 5alpha-reductase gene expression in rat C6 glioma cells via a mechanism involving Sp1 and Sp3 transcription factors","volume":"41","author":"Her","year":"2010","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.pharep.2013.08.011_bib0090","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.bbagen.2011.02.006","article-title":"p53 in trichostatin A induced C6 glioma cell death","volume":"1810","author":"Hsu","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharep.2013.08.011_bib0095","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2006-07-027326","article-title":"Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress","volume":"109","author":"Isham","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pharep.2013.08.011_bib0100","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3892\/ol.2013.1190","article-title":"Epigenetic effects of the natural flavonolignan silibinin on colon adenocarcinoma cells and their derived metastatic cells","volume":"5","author":"Kauntz","year":"2013","journal-title":"Oncol Lett"},{"key":"10.1016\/j.pharep.2013.08.011_bib0105","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/icb.2011.100","article-title":"HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications","volume":"90","author":"Khan","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.pharep.2013.08.011_bib0110","doi-asserted-by":"crossref","first-page":"e7443","DOI":"10.1371\/journal.pone.0007443","article-title":"GSK3beta regulates differentiation and growth arrest in glioblastoma","volume":"4","author":"Korur","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.pharep.2013.08.011_bib0115","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/11532190-000000000-00000","article-title":"Current and emerging treatment strategies for cutaneous T-cell lymphoma","volume":"70","author":"Lansigan","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.pharep.2013.08.011_bib0120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ccr.2007.12.005","article-title":"Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells","volume":"13","author":"Lee","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharep.2013.08.011_bib0125","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1158\/1055-9965.EPI-10-0454","article-title":"Global histone modification patterns as prognostic markers to classify glioma patients","volume":"19","author":"Liu","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.pharep.2013.08.011_bib0130","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/1471-2407-8-243","article-title":"Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas","volume":"8","author":"Lucio-Eterovic","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharep.2013.08.011_bib0135","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1750-3639.2011.00536.x","article-title":"Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets","volume":"21","author":"Malzkorn","year":"2011","journal-title":"Brain Pathol"},{"key":"10.1016\/j.pharep.2013.08.011_bib0140","first-page":"5171","article-title":"Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents","volume":"29","author":"Minniti","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pharep.2013.08.011_bib0145","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/bies.201000061","article-title":"Epigenetic cancer therapy: proof of concept and remaining challenges","volume":"32","author":"Mund","year":"2010","journal-title":"Bioessays"},{"key":"10.1016\/j.pharep.2013.08.011_bib0150","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2990.2010.01132.x","article-title":"Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells","volume":"37","author":"Orzan","year":"2011","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.pharep.2013.08.011_bib0155","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.pharep.2013.08.011_bib0160","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1128\/MCB.24.12.5197-5208.2004","article-title":"Glucose and nitrogen regulate the switch from histone deacetylation to acetylation for expression of early meiosis-specific genes in budding yeast","volume":"24","author":"Pnueli","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.pharep.2013.08.011_bib0165","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/bcr2354","article-title":"BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A","volume":"11","author":"Puppe","year":"2009","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.pharep.2013.08.011_bib0170","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/35020506","article-title":"Regulation of chromatin structure by site-specific histone H3 methyltransferases","volume":"406","author":"Rea","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.pharep.2013.08.011_bib0175","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1479-5876-7-77","article-title":"Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors","volume":"7","author":"Sarin","year":"2009","journal-title":"J Transl Med"},{"key":"10.1016\/j.pharep.2013.08.011_bib0180","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.2165\/11596690-000000000-00000","article-title":"Epigenetic-based therapies in cancer: progress to date","volume":"71","author":"Song","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.pharep.2013.08.011_bib0185","doi-asserted-by":"crossref","first-page":"9211","DOI":"10.1158\/0008-5472.CAN-09-1622","article-title":"EZH2 is essential for glioblastoma cancer stem cell maintenance","volume":"69","author":"Suv\u00e0","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharep.2013.08.011_bib0190","doi-asserted-by":"crossref","first-page":"25309","DOI":"10.1074\/jbc.M101914200","article-title":"Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3","volume":"276","author":"Tachibana","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharep.2013.08.011_bib0195","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1756-8722-3-5","article-title":"Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents","volume":"3","author":"Tan","year":"2010","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.pharep.2013.08.011_bib0200","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2217\/epi.11.82","article-title":"Promises and challenges of anticancer drugs that target the epigenome","volume":"3","author":"Verbrugge","year":"2011","journal-title":"Epigenomics"}],"updated-by":[{"DOI":"10.1016\/j.pharep.2014.08.012","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000}}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114014000188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114014000188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:35:14Z","timestamp":1752611714000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2013.08.011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S1734114014000188"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2013.08.011","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}